Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27:2606-2611
doi: 10.1161/ATVBAHA.107.152694
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, Y. T.Y.
Right arrow Articles by Bishop-Bailey, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, Y. T.Y.
Right arrow Articles by Bishop-Bailey, D.
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27:2606.)
© 2007 American Heart Association, Inc.


Vascular Biology

Farnesoid X Receptor Ligands Inhibit Vascular Smooth Muscle Cell Inflammation and Migration

Yoyo T.Y. Li; Karen E. Swales; Gareth J. Thomas; Timothy D. Warner; David Bishop-Bailey

From the Centre of Translational Medicine & Therapeutics (Y.T.Y.L., K.E.S., T.D.W., D.B.B.), William Harvey Research Institute, and the Tumour Biology Laboratory (G.J.T.), Cancer Research UK Clinical Centre, Barts & The London, Queen Mary University of London, UK.

Correspondence to Dr. David Bishop-Bailey, Centre of Translational Medicine & Therapeutics, William Harvey Research Institute, Barts & The London, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, United Kingdom, E-mail d.bishop-bailey{at}qmul.ac.uk

Objective— The farnesoid X receptor/bile acid receptor (FXR; NR1H4) is a ligand-activated transcription factor that regulates bile acid and lipid homeostasis, and is highly expressed in enterohepatic tissue. FXR is also expressed in vascular tissue. We have investigated whether FXR regulates inflammation and migration in vascular smooth muscle cells.

Methods and Results— The FXR target gene, small heterodimer partner (SHP), was induced in vascular smooth muscle cells after treatment with synthetic FXR ligands, GW4064, or 6{alpha}-ethyl-chenodeoxycholic acid. FXR ligands induced smooth muscle cell death and downregulated interleukin (IL)-1β–induced inducible nitric oxide synthase and cyclooxygenase-2 expression. In addition, FXR ligands suppressed smooth muscle cell migration stimulated by platelet-derived growth factor-BB. Reporter gene assays showed that FXR ligands activated an FXR reporter gene and suppressed IL-1β–induced nuclear factor (NF)-{kappa}B activation and iNOS in a manner that required functional FXR and SHP.

Conclusion— Our observations suggest that a FXR-SHP pathway may be a novel therapeutic target for vascular inflammation, remodeling, and atherosclerotic plaque stability.

FXR is expressed in vascular smooth muscle cells. Here we show that in addition to antiproliferative properties, activation of FXR inhibits inflammation and migration of vascular smooth muscle cells. FXR may therefore be a novel direct target for vascular disease.


Key Words: FXR • vascular smooth muscle • iNOS • COX-2 • cell migration




This article has been cited by other articles:


Home page
Am. J. Physiol. Renal Physiol.Home page
X. X. Wang, T. Jiang, Y. Shen, L. Adorini, M. Pruzanski, F. J. Gonzalez, P. Scherzer, L. Lewis, S. Miyazaki-Anzai, and M. Levi
The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria
Am J Physiol Renal Physiol, December 1, 2009; 297(6): F1587 - F1596.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
L. Piqueras, M. J. Sanz, M. Perretti, E. Morcillo, L. Norling, J. A. Mitchell, Y. Li, and D. Bishop-Bailey
Activation of PPAR{beta}/{delta} inhibits leukocyte recruitment, cell adhesion molecule expression, and chemokine release
J. Leukoc. Biol., July 1, 2009; 86(1): 115 - 122.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
C. J. Nelson, J. P. Otis, and H. V. Carey
A role for nuclear receptors in mammalian hibernation
J. Physiol., May 1, 2009; 587(9): 1863 - 1870.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. Das, U. Yaqoob, D. Mehta, and V. H. Shah
FXR Promotes Endothelial Cell Motility Through Coordinated Regulation of FAK and MMP-9
Arterioscler Thromb Vasc Biol, April 1, 2009; 29(4): 562 - 570.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
H. B. Hartman, K. Lai, and M. J. Evans
Loss of small heterodimer partner expression in the liver protects against dyslipidemia
J. Lipid Res., February 1, 2009; 50(2): 193 - 203.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
P. Lefebvre, B. Cariou, F. Lien, F. Kuipers, and B. Staels
Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation
Physiol Rev, January 1, 2009; 89(1): 147 - 191.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
T. Kida, T. Murata, M. Hori, and H. Ozaki
Chronic stimulation of farnesoid X receptor impairs nitric oxide sensitivity of vascular smooth muscle
Am J Physiol Heart Circ Physiol, January 1, 2009; 296(1): H195 - H201.
[Abstract] [Full Text] [PDF]